Evaluation of the association between sexual dysfunction and demyelinating plaque location and number in female multiple sclerosis patients

Basit Öğe Kaydı
dc.authoridCordano, Christian/0000-0002-1413-0442
dc.authoridAksoy, Dürdane/0000-0003-1981-084X
dc.authoridsolmaz, volkan/0000-0002-9045-2347
dc.authorwosidCordano, Christian/ABC-3629-2020
dc.authorwosidAksoy, Dürdane/B-7835-2017
dc.contributor.authorSolmaz, Volkan
dc.contributor.authorOzlece, Hatice Kose
dc.contributor.authorHim, Aydin
dc.contributor.authorGunes, Ayfer
dc.contributor.authorCordano, Christian
dc.contributor.authorAksoy, Durdane
dc.contributor.authorCelik, Yahya
dc.date.accessioned2024-06-12T11:08:49Z
dc.date.available2024-06-12T11:08:49Z
dc.date.issued2018
dc.departmentTrakya Üniversitesien_US
dc.description.abstractPurpose: To investigate the frequency of sexual dysfunction (SD) in female multiple sclerosis (MS) patients and to explore its association with the location and number of demyelinating lesions. Material and Methods: We evaluated 42 female patients and 41 healthy subjects. All patients underwent neurological examination and 1.5 T brain and full spinal MRI. All subjects completed the female sexual function index (FSFI), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), and Short-Form 36 Quality of Life Scale (SF-36). All participants were also evaluated for serum thyroid stimulating hormone (TSH), T4, estradiol, and total testosterone. Results: No statistically significant differences between the MS and control groups were found for age, body mass index (BMI), serum TSH, T4, E2, and total testosterone level. MS patients had a statistically significantly lower FSFI and SF-36 scores and higher BDI and BAI scores compared with healthy subjects. The location and number of demyelinating lesions were not associated with SD. Conclusion: In our cohort, this difference in SD appears unrelated to the location and number of demyelinating lesions. These findings highlight the importance of the assessment and treatment of psychiatric comorbidities, such as depression and anxiety, in MS patients reporting SD.en_US
dc.identifier.doi10.1080/01616412.2018.1462752
dc.identifier.endpage688en_US
dc.identifier.issn0161-6412
dc.identifier.issn1743-1328
dc.identifier.issue8en_US
dc.identifier.pmid29663848en_US
dc.identifier.scopus2-s2.0-85045463195en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage683en_US
dc.identifier.urihttps://doi.org/10.1080/01616412.2018.1462752
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22579
dc.identifier.volume40en_US
dc.identifier.wosWOS:000444091900009en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofNeurological Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMultiple Sclerosisen_US
dc.subjectSexual Dysfunctionen_US
dc.subjectDemyelinating Lesionsen_US
dc.subjectMagnetic Resonanceen_US
dc.subjectWomenen_US
dc.titleEvaluation of the association between sexual dysfunction and demyelinating plaque location and number in female multiple sclerosis patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu